FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:522-524 August 12, 1999 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Durham, S. R. PubMed Citation

Allergic rhinitis, or hay fever, afflicts 10 to 20 percent of people in the United States and northern Europe. The disease occurs either during the seasons of airborne pollens and molds or throughout the year, triggered by indoor allergens such as dust mites, house pets, cockroaches, and molds. Allergic rhinitis usually starts in childhood, on average at about the age of 10 years. Like that of asthma, its prevalence is rising, especially in urban areas, for obscure reasons. Although many assume that allergic rhinitis is more of a nuisance than a clinically significant health problem, it is responsible for $6 . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Bousquet, J. (2001). Pro: Immunotherapy Is Clinically Indicated in the Management of Allergic Asthma. Am. J. Respir. Crit. Care Med. 164: 2139-2140 [Full Text]  
• Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., Metzger, W. J., The rhuMAb-E25 Study Group, (1999). Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody. NEJM 341: 1966-1973 [Abstract] [Full Text]